liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Rufinamide: A double-blind, placebo-controlled proof of principle trial in patients with epilepsy
Linköping University, Faculty of Health Sciences. Linköping University, Department of Clinical and Experimental Medicine, Geriatric .
Centro Per l'Epilessia, Ospedale S. Paolo, Milan, Italy.
National Centre for Epilepsy, Postbox 900, N-1337 Sandvika, Norway.
Van Parys, J.A., Instituut Voor Epilepsie Bestrijding, Heemstede, Netherlands.
Show others and affiliations
2001 (English)In: Epilepsy Research, ISSN 0920-1211, Vol. 43, no 2, 115-124 p.Article in journal (Refereed) Published
Abstract [en]

Objective: This was the first proof of principle clinical trial assessing the efficacy and safety of rufinamide as adjunctive therapy in epileptic patients. The pharmacokinetic (PK) profile of rufinamide was also determined. Methods: Fifty patients with diagnoses of partial or primary generalized tonic-clonic seizures were enrolled in this 28-day double-blind, placebo-controlled, weekly rising dose (400-1600 mg/day) trial. PK profiles were obtained after administration of single-dose rufinamide prior to and after the Double-blind phase. Results: In the evaluable patient population, seizure frequency decreased by 41% in the rufinamide group and increased by 52% in the placebo group (P = 0.040). Thirty-nine percent (39%) of rufinamide-treated and 16% of placebo-treated patients experienced reduction in seizure frequency of at least 50% relative to baseline (P = 0.096). Safety: Treatment-emergent adverse events (AEs) consisted mainly of neurologic signs and symptoms commonly associated with antiepileptic drugs (AEDs). Pharmacokinetics: At steady state, rufinamide reached a peak plasma concentration with a mean time (Tmax) of 3.4 h and a mean half-life (t1/2) of 7.3 h. No autoinduction of rufinamide metabolism occurred. Rufinamide did not influence the plasma concentration of carbamazepine, phenytoin or valproate when added to these single AED regimens. Conclusion: Rufinamide has been shown, in this proof of principle trial, to be safe and effective in reducing seizure frequency in epileptic patients with no relevant influence on the metabolism of other AEDs. © 2001 Elsevier Science B.V.

Place, publisher, year, edition, pages
2001. Vol. 43, no 2, 115-124 p.
Keyword [en]
AED, Antiepileptic agents, Pharmacokinetics, Rufinamide, Seizures
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-47472DOI: 10.1016/S0920-1211(00)00185-6OAI: diva2:268368
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2011-01-13

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Pålhagen, Sven
By organisation
Faculty of Health SciencesGeriatric
In the same journal
Epilepsy Research
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 26 hits
ReferencesLink to record
Permanent link

Direct link